Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for ophthalmic diseases in the United States. The company's lead product, KIO-301, is a potential vision-restoring small molecule currently in Phase 1 clinical trial, designed to restore vision in patients with inherited and age-related degenerative retinal diseases. Additionally, Kiora Pharmaceuticals is developing KIO-101, an eye drop in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis and non-infectious posterior uveitis, as well as KIO-201, an eye drop in Phase 3 clinical trial for corneal wound repair after refractive surgery.

Products

• KIO-301 - Vision-restoring small molecule

• KIO-101 - Eye drop for ocular presentation of rheumatoid arthritis and non-infectious posterior uveitis

• KIO-201 - Eye drop for corneal wound repair after refractive surgery